Komentarz do badania JUPITER Komentarz

##plugins.themes.bootstrap3.article.main##

Tomasz Grodzicki
Magdalena Strach

Abstrakt

Brak

Pobrania

Dane pobrania nie są jeszcze dostepne

##plugins.themes.bootstrap3.article.details##

Jak cytować
Grodzicki , T., & Strach , M. (2008). Komentarz do badania JUPITER . Kardiologia W Praktyce, 2(4), 168-169. Pobrano z https://journalsmededu.pl/index.php/kwp/article/view/1675
Dział
Artykuły

Bibliografia

1. Downs J.R., Clearfield M., Weis S., Whitney E., Shapiro D.R., Beere P.A., Langendorfer A., Stein E.A., Kruyer W., Gotto A.M. Jr: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998, 279: 1615-22.
2. Sever P.S., Dahlof B., Poulter N.R., Wedel H., Beevers G., Caulfield M., Collins R., Kjeldsen S.E., Kristinsson A., McInnes G.T., Mehlsen J., Nieminen M., O’Brien E., Ostergren J.: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003, 361: 1149-58.
3. Pearson T.A., Mensah G.A., Alexander R.W. et al.: Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003, 107: 499.
4. Albert M.A., Glynn R.J., Ridker P.M.: Plasma concentration of C-reactive protein and the calculated Framingham Coronary Heart Disease Risk Score. Circulation 2003, 108: 161-167.